Intravenous (IV) Ibuprofen Market Synopsis:<\/p>\n
Intravenous (IV) Ibuprofen Market Size Was Valued at USD 6.45 Billion in 2023, and is Projected to Reach USD 11.87 Billion by 2032, Growing at a CAGR of 7.0 % From 2024-2032.<\/p>\n
The Intravenous (IV) Ibuprofen market involves the sales and uses of the ibuprofen administered intravenously, meaning directly into the patient’s bloodstream. Pain and inflammation therapeutic delivery using this method is most preferred when treating patients in conducting clinical procedures where they cannot take tablets orally. IV ibuprofen is commonly prescribed following surgery, in accident and emergency, and for patients who need rapid onset analgesia, making it a core part of the hospital analgesic armamentarium.<\/p>\n
The market for the IV ibuprofen has continuously been growing because of increased use in hospitals and clinics where pain control is important after surgery or during treatment. Iv ibuprofen unlike orally administered ibuprofen does not go through the digestive tract and therefore has much faster relief especially for patients in post \u2013 operative or trauma case whose inflammation need to be well regulated to have effective pain relief. This aspect has created its demand in acute or critical care, especially in the well-developed healthcare systems that require potential pain management systems.<\/p>\n
Also, the growth of interventions such as the greater occurrence of surgical operations and the improved knowledge of non-opioid pain relievers play a significant role in the development of market. Every healthcare provider and governments wish to overcome the threats posed by opioid dependency therefore pushing for the take of non-opioid analgesics such as IV ibuprofen. The process of manufacturing intravenous NSAIDs and improving its efficiency and safety standard from various adverse effects including gastrointestinal bleeding is being pursued by most of the leading pharmaceutical industries to meet the global demand and drive the market towards further growth which is evident via ongoing research for refining ibuprofen as an intravenous NSAID.<\/p>\n
Intravenous (IV) Ibuprofen Market Trend Analysis:<\/p>\n
Rising Demand for Non-Opioid Pain Management Solutions<\/p>\n
Increase in the death rates of the opioid crisis has led to its replacement by Non-Opioid Analgesics which in return will grow the market for IV Ibuprofen. Many governments, healthcare facilities, and non-profit organizations have lately openly collaborated with each other on the fight against opioids and other similar drugs and constantly seek medical treatments that are not as likely to cause dependency. In this respect, IV ibuprofen has become a vital choice in a hospital and clinical practice since it is not only useful in pain relief, but also in control of inflammation, which is critical in traumatology and treatment following surgery.<\/p>\n
The trend also finds support in calls for better postoperative pain management that would reduce patients\u2019 risks and bolster more rapid recovery. IV ibuprofen is now sought to be marketed as a primary treatment in the DS service offering; particularly in developed healthcare segments. There will be an increase in the development of non-opioid pain relief solutions as healthcare providers embrace new trends in technical approaches to pain relief with the combination of analgesic and anti-inflammatory properties of IV ibuprofen.<\/p>\n
Expanding Healthcare Infrastructure in Emerging Markets<\/p>\n
The IV ibuprofen market finds another potential in emergent markets where the rates of development of the healthcare sector are higher to meet the demand for patients\u2019 treatment. Today most of the countries in Asia-Pacific, Latin America, and some of African nations are investing in the development of hospitals, infrastructure that can deliver the required healthcare services, and in making IV medications, including ibuprofen, available and easily accessible to the patients. They expect that as these regions increases number of hospital and medical facilities, the IV ibuprofen will be increasingly adopted in these regions, especially if governments set aside funds for cheap and efficient pain relief.<\/p>\n
Besides, most of these regions are experiencing a rise in medical tourism that has been accompanied by the introduction of efficient IVDS. This, along with increased procedural and trauma surgeries, is contributing to a good IV ibuprofen market opportunity. To foster these opportunities, companies around the world set up their supply chains and partnering in these territories to meet a fast-orising healthcare industry whose demands such as non-opioid pain relief are on the rise.<\/p>\n
Intravenous (IV) Ibuprofen Market Segment Analysis:<\/p>\n
Intravenous (IV) Ibuprofen Market is Segmented on the basis of Type, Strength, Age Group, Distribution Channel, and Region<\/p>\n
By Type, Pain\/Inflammatory segment is expected to dominate the market during the forecast period<\/p>\n
By type, Pain\/Inflammatory segment is expected to have the largest growth in the IV Ibuprofen market during the period 2018-2023 as it is an essential component in delivering prompt and effective relief from pain across hospitals to manage both acute and chronic diseases. IV ibuprofen was found to have an efficacy to treat both pain and inflammation and was recommended for postsurgical pains, emergency, and for patients who cannot take oral medications. This dual function is especially useful in patients undergoing surgery and those with a traumatic injury where inflammation contributes to pain. In addition, the growing worldwide concern for non-opioid pain management reinforces the dependable efficacy of IV ibuprofen and its low propensity for dependency vis-\u00e0-vis opioid analgesics in the supporting of the Pain\/Inflammatory segment of the business.<\/p>\n
By Strength, 100 Mg Dose segment expected to held the largest share <\/p>\n
The IV ibuprofen 100 mg dose segment is likely to have the largest share due to its efficacy\/safety profile for different patient requirements. It is used for intermediate pain controlling as well as decreasing inflammation frequency, and is effectively used in both favourite and emergency healthcare practices in burn centers. This, in addition to patients\u2019 preferences and needs, is further supported by its application to usage for a wide range of age groups and medical conditions, which makes it a homogenized, easy to manage platform for medical personnel. The therapeutic effect of an oral dose of 100 mg presents a very quick onset with mild side effects, and as such, it is best used for short-term treatments, for instance, after surgery or other trauma. As healthcare providers focus on safe, effective, and flexible options for pain management, the 100 mg dose segment is still an outstanding market option.<\/p>\n
Intravenous (IV) Ibuprofen Market Regional Insights: <\/p>\n
North America is Expected to Dominate the Market Over the Forecast period <\/p>\n
North America continues to dominate the IV ibuprofen market in 2023 due to high availability of health care facilities, high surgery rates and the growing awareness of non-opioid analgesic management. This market significantly occupies almost one third of a world market share, namely 35%. The United States has contributed significantly due to the restrictive policies of prescription of opioids in the US and more importantly due to the shift towards the use of non-opioid analgesic products in clinical services. Also, having significant industry players and this steadily developed health care reimbursement system make North America maintain its commanding market position. In addition, the increasing proportion of elderly people and the corresponding increase in the incidence of chronic diseases will also maintain the demand for IV ibuprofen, and North America is likely to dominate this field.<\/p>\n
Active Key Players in the Intravenous (IV) Ibuprofen Market:<\/p>\n
Abbott Laboratories (USA)<\/p>\n
AuroMedics Pharma LLC (USA)<\/p>\n
Baxter International Inc. (USA)<\/p>\n
Bayer AG (Germany)<\/p>\n
Cumberland Pharmaceuticals (USA)<\/p>\n
Dr. Reddy\u2019s Laboratories (India)<\/p>\n
Exela Pharma Sciences LLC (USA)<\/p>\n
Fresenius Kabi AG (Germany)<\/p>\n
Hikma Pharmaceuticals (UK)<\/p>\n
Novartis AG (Switzerland)<\/p>\n
Perrigo Company (Ireland)<\/p>\n
Pfizer Inc. (USA)<\/p>\n
Sandor Medicaids Pvt Ltd (India)<\/p>\n
Sun Pharmaceutical Industries Ltd (India)<\/p>\n
Other Active Players<\/p>\n","protected":false},"excerpt":{"rendered":"
The Intravenous (IV) Ibuprofen market involves the sales and uses of the ibuprofen administered intravenously, meaning directly into the patient’s bloodstream. Pain and inflammation therapeutic delivery using this method is most preferred when treating patients in conducting clinical procedures where they cannot take tablets orally. IV ibuprofen is commonly prescribed following surgery, in accident and emergency, and for patients who need rapid onset analgesia, making it a core part of the hospital analgesic armamentarium.<\/p>\n","protected":false},"featured_media":7530,"template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[194],"product_tag":[],"class_list":["post-10229","product","type-product","status-publish","has-post-thumbnail","product_cat-healthcare-life-sciences","first","instock","virtual","purchasable","product-type-simple"],"acf":[],"yoast_head":"\n